Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Enterprise Value (2021 - 2025)

Historic Enterprise Value for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$208.4 million.

  • Prime Medicine's Enterprise Value fell 2215.87% to -$208.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$208.4 million, marking a year-over-year decrease of 2215.87%. This contributed to the annual value of -$187.4 million for FY2024, which is 6129.35% down from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Enterprise Value is -$208.4 million, which was down 2215.87% from -$98.3 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Enterprise Value peaked at -$92.2 million during Q2 2022, and registered a low of -$286.1 million during Q4 2022.
  • For the 5-year period, Prime Medicine's Enterprise Value averaged around -$177.8 million, with its median value being -$170.6 million (2024).
  • Over the last 5 years, Prime Medicine's Enterprise Value had its largest YoY gain of 5937.84% in 2023, and its largest YoY loss of 11815.28% in 2023.
  • Over the past 5 years, Prime Medicine's Enterprise Value (Quarter) stood at -$253.7 million in 2021, then fell by 12.78% to -$286.1 million in 2022, then surged by 59.38% to -$116.2 million in 2023, then plummeted by 61.29% to -$187.4 million in 2024, then dropped by 11.19% to -$208.4 million in 2025.
  • Its Enterprise Value was -$208.4 million in Q3 2025, compared to -$98.3 million in Q2 2025 and -$140.3 million in Q1 2025.